HVO

hVIVO plc

hVIVO plc Upgraded Full Year Revenue and EBITDA Guidance

hVIVO plc (Euronext & LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its unaudited interim results for the six-month period ended 30 June

hVIVO plc

A day in the life of a clinical trial volunteer

What does a day look like as a clinical trial volunteer? FluCamp is a leading clinical research organization focused on studying and developing treatments for respiratory illnesses. We conduct clinical

hVIVO plc

Biotech hVIVO expanding clinical trial capacity

The Irish-founded biotech Hvivo is expanding its operations in London to meet growing demand for its human challenge clinical trial services. Clinical-trial specialist biotech hVIVO has announced the planned expansion

hVIVO plc

Hvivo plans larger London facility to meet demand

Pharmaceutical services firm Hvivo, formerly Open Orphan, has announced plans to open a larger facility in response to the company’s growing order book. Hvivo focuses on advancing research in infectious

Fidelity Japan Trust
Discover how Japan's Nikkei index rose amidst challenges faced by Fast Retailing, highlighting the market's complexities and opportunities for investors.
Fidelity China Special Situations
Chinese and Hong Kong stocks gain on promising data and policy support from Beijing. Shanghai and Hang Seng indexes rise amid positive investor sentiment.
Fidelity Emerging Markets
Indian stocks poised for growth despite challenges, with global trends and potential rate cuts boosting investor confidence.